Biopsychosocial correlates of somatic symptom burden in chronic kidney disease: results of the Hamburg City Health Study (HCHS)

Birte Jessen[a,b], Bernd Löwe[b], Raphael Twerenbold[c], Martin Härter[d], Volker Harth[e], Hanno Hoven[e], Christian Schmidt-Lauber*[f,g], Tobias B. Huber*[f,g], Meike Shedden-Mora*[a,b]

[a] *Institute for Clinical Psychology and Psychotherapy & Department of Psychology, Medical School Hamburg, Hamburg, Germany*

[b] *Department of Psychosomatic Medicine and Psychotherapy, University Medical Center Hamburg-Eppendorf, Hamburg, Germany*

[c] *University Center of Cardiovascular Science, Department of Cardiology, University Heart and Vascular Center Hamburg, University Medical Center Hamburg-Eppendorf, Hamburg, Germany & German Center for Cardiovascular Research (DZHK) Partner Site Hamburg-Kiel-Lübeck, Germany*

[d] *Department of Medical Psychology and Institute for Psychotherapy, University Medical Center Hamburg-Eppendorf, Hamburg, Germany*

[e] *Institute for Occupational and Maritime Medicine (ZfAM), University Medical Center Hamburg-Eppendorf, Hamburg, Germany*

[f] *III. Department of Medicine, University Medical Center Hamburg-Eppendorf, Germany*

[g] *Hamburg Center for Kidney Health (HCKH), University Medical Center Hamburg-Eppendorf, Hamburg, Germany*

** shared last authorship*

Correspondence to:

Birte Jessen, MSc

Department of Psychology, Medical School Hamburg, Hamburg, Germany

Am Kaiserkai 1

20457 Hamburg, Germany

Telephone: +49 40 36122649305

E-mail: birte.jessen@medicalschool-hamburg.de

Word count (maximum 3500, excluding abstract (300 words)): 268 (Abstract) 3499 (excluding abstract, references, the article information section, tables and figure legends)

Number of figures, tables, boxes, references (maximum 50 references): 0, 3, 0, 50

Abstract

Background: Persistent somatic symptoms (PSS) in individuals with chronic kidney disease (CKD) occur across all stages and impact patients' quality of life, morbidity and mortality. We aimed to unravel associations between biopsychosocial factors and symptom burden in individuals with CKD. **Methods:** This cross-sectional study analysed individuals with CKD (estimated glomerular filtration rate (eGFR) <60 mL/min/1.73m^2) from the first 10,000 participants of the population-based Hamburg City Health Study (HCHS). Somatic symptom burden (PHQ-15) was the primary outcome. Its association with potential biological (e.g., eGFR), psychological (e.g., depressive symptoms), and sociodemographic correlates was analysed in a multivariate prediction model. Correlates were compared to healthy controls and individuals with coronary heart disease (CHD). **Results:** Somatic symptom burden in patients with non-dialysis CKD (n = 582, mean age: 69.58 years; 44.7% women; mean baseline eGFR: 52 mL/min/1.73m^2) increased with lower eGFR (r = -.161, p < .001). However, in a stepwise multiple linear regression model, eGFR was not correlated with symptom burden. In contrast, female sex, coronary heart disease, self-reported general health, proneness to illness, and depressive symptoms were associated with somatic symptom burden. Correlates of somatic symptom burden in patients with CHD (n = 618, mean age: 67.13 years; 24.1% women; mean baseline eGFR: 81 mL/min/1.73m^2) and matched healthy controls (n = 582, mean age: 69.58 years; 44.7% women; mean baseline eGFR: 81 mL/min/1.73m^2) were comparable. **Conclusion:** Somatic symptom burden in CKD was only marginally related to the eGFR but rather to biopsychosocial factors. Therefore, taking a biopsychosocial perspective on PSS in CKD is important.

Key words: Biopsychosocial correlates, chronic kidney disease, Hamburg City Health Study, persistent somatic symptoms, symptom burden

Key points

- Kidney function (GFR) correlated with somatic symptom burden bivariately, but not in the multiple regression model.
- Female sex, coronary heart disease, self-reported general health, proneness to illness and depressive symptoms correlated to symptom burden.
- Similar biopsychosocial correlates of symptom burden were observed in individuals with CKD, coronary heart disease (CHD) and controls.

Introduction

Persistent somatic symptoms (PSS) describe subjectively bothersome somatic complaints that are present on most days for at least several months, regardless of their cause.[1,2] PSS occur in approximately 15% of the general population[3], and in most chronic diseases.[1-4] PSS in chronic kidney disease (CKD) appear in all stages and are associated with quality of life (QoL), morbidity and mortality.[5,6] Recent evidence highlights that even individuals with early CKD report a high somatic symptom burden with most prevalent symptoms being fatigue (70%), pruritus (46%) and bone or joint pain (55%).[7,8]

Contrary to clinical expectations, scientific evidence if symptom burden severity is related to CKD severity remains inconclusive. Reported correlations between the estimated glomerular filtration rate (eGFR) and general subjective symptom burden are weak[5,8] and overall symptom burden[4,7] is comparable across non-dialysis and end-stage kidney disease.[5,9] In contrast to a comparable overall symptom burden however, specific symptoms, namely lack of appetite, fatigue, impaired sex life, and cramps were recently found to increase with CKD severity.[7] Symptom burden in CKD seems to be comparable to that of other chronic diseases such as coronary heart disease (CHD)[10], or even terminal malignant conditions.[11] In fact, patients often report that disabling somatic symptoms are the primary disease burden in their lives.[12]

Although the etiology of PSS in CKD is poorly understood and researched, a stronger focus on disease-overarching biopsychosocial factors contributing to PSS across diseases has recently been proposed, emphasizing a biopsychosocial perspective.[1,2,4] From this perspective, psychological and health-related factors such as subjective illness beliefs, expectations, depression, anxiety, cognitive-perceptual mechanisms, emotion regulation strategies, and adverse childhood experiences are thought to contribute to somatic symptom burden.[13,14] In CKD, initial evidence highlights the importance of depression and anxiety, which were either associated with elevated somatic symptom burden and adverse outcomes[15-17] or higher compared to controls.[18,19] Adverse childhood experiences were identified as major

predictor of symptom burden and mental and physical health[20,21] and were associated with higher all-cause mortality in individuals with CKD.[18,22] Other factors identified as predictors of non-adherence, depression, morbidity, mortality, and lower QoL in CKD include patients' illness perceptions[19] and physical inactivity.[23-25]

While our knowledge on biopsychosocial correlates of PSS in CKD is still limited, accumulating evidence suggests pathophysiological mechanisms of PSS in CKD being comparable to those in somatoform and functional disorders.[26] The development of PSS in CKD is probably rather driven by the complex interplay of biomedical (comorbidities), treatment-related (medication side effects, dialysis), and psychological factors (depression, anxiety).[27]

The primary study aim was to analyse cross-sectional sociodemographic, biological, psychological and health-related correlates of somatic symptom burden in individuals with CKD. We hypothesized that psychosocial factors (depression, anxiety) are stronger associated with somatic symptom burden in individuals with CKD than biomedical factors (eGFR, medication). As secondary outcome, we analysed biopsychosocial correlates of QoL. Third, we aimed to compare the impact of biopsychosocial correlates on symptom burden in CKD with a healthy and a somatic control group with coronary heart disease (CHD). Comparing CKD and CHD may provide important insights into disease-specific and disease-overarching mechanisms. We expected psychosocial correlates of somatic symptom burden to be comparable in individuals with CKD and matched somatic and healthy controls.

Materials and Methods

Study design and population

Data was taken from the Hamburg City Health Study (HCHS), a prospective, long-term, population-based cohort study designed to discover important risk and prognostic factors in major chronic diseases.[28] The HCHS includes individuals between 45 and 74 years of age recruited from the general population of Hamburg, Germany via mail. Cross-sectional data from the first 10,000 participants, collected between February 2016 and November 2018, were available for this analysis. Based on this cohort, we analysed three different groups in this cross-sectional study. First, individuals with CKD, defined by an eGFR <60ml/min/1.73m² were identified.[29] The eGFR was calculated with the 2009 Chronic Kidney Disease Epidemiology Collaboration (CKD-Epi) formula for creatinine.[29,30] Creatinine measurements were performed as described recently[31], and eGFR was staged according to recommendations of the Kidney Disease: Improving Global Outcomes (KDIGO) Collaborative.[29] Only a comorbid coronary heart disease was not excluded in the CKD group. Second, a control group with coronary heart disease (CHD) and an eGFR >60ml/min/1.73m^2 was defined to compare correlates of somatic symptom burden to a comparable chronic illness. A certain overlap or simultaneous presence of CKD and CHD should be mentioned, but these subjects were categorised in the CKD group. Third, a healthy control sample with neither CHD nor CKD matched in sex, age and education status with no tolerance for deviations and furthermore no distinctions regarding age, sex and educational status to the CKD-cohort using case-control-matching via SPSS was included. Later, demographic and clinical variables across CKD stages were compared. Stages ≥ 3b were combined due to small number of participants. The HCHS study protocol was approved by the ethics committee of the State of Hamburg Chamber of Medical Practitioners (PV5131) and was registered at ClinicalTrial.gov (NCT03934957). The analysis was preregistered at the Open Science Framework (https://osf.io/58s2r).

Assessment and study outcomes:

*Primary Outcome**: Somatic symptom burden***

Somatic symptom burden was measured using the Patient-Health-Questionnaire-15 (PHQ-15), a self-report questionnaire measuring the severity of 15 symptomatic symptoms (see S2) on a three-point scale ranging from 0 (*not bothered at all)* to 2 (*bothered a lot).* Scores range from 0 to 30, categorized as *low* (0-4 points), *medium* (5-9 points) and *high* (≥10 points).[32] Internal consistency and test-retest reliability and a good fit for large-scale studies of the score has been shown in different studies.[33]

Secondary Outcome: ***Quality of Life***

QoL was measured using the European Quality of Life 5 Dimensions 5 Level Version (EQ5D-5L), a standardised 6-item self-report questionnaire with five dimensions (*mobility*, *self-care*, *usual activities*, *pain/discomfort* & *anxiety/depression*) rated on a 5-point scale. The sixth item represents a visual analogue scale from 0-100 rating subjectively perceived general health status.[34]

Biopsychosocial correlates

Sociodemographic factors included age, sex and education status staged according to the International Standard Classification of Education (ISCED 2011) of *low* (Levels 0-2) , *medium* (Levels 3-4), *high* (Levels 5-8).[35] Vitals and non-renal biomarkers such as high sensitive C-reactive protein (hsCRP) were measured as described.[31,36]

Comorbidities were assessed using composite scores*,* for coronary heart disease (self-reported diagnosis of coronary artery disease, myocardial infarction, balloon dilatation of the coronary arteries (PTCA), stent implantation or bypass surgery), arterial hypertension (antihypertensive medication, systolic blood pressure >140mmHg, diastolic blood pressure >90mmHg or self-report), diabetes mellitus (self-report, antidiabetic medication, fasting glucose >126mg/dl, non-fasting glucose >200mg/dl), and dyslipidaemia (LDL/HDL ratio >3.5 or lipid modifying drugs). Medication[28] and the presence of further chronic illnesses (asthma bronchiale, chronic obstructive bronchitis and cancer) were assessed via self-report.

Health related factors were measured with variables from the DEGS study (study on the health of adults in Germany). General health, proneness to illness and the expectancy of deterioration of health states were rated on a five-point scale (e.g. general health: 1 *excellent* to 5 *bad*). Physician visits in the past year were assessed via self-report.[37]

Smoking behaviour was assessed via self-report and dichotomized into *yes* and *no* (combination of non-smokers and former smokers).

Physical activity was measured with single items from a spaq (seasonal pattern assessment questionnaire) based on the *European Prospective Investigation into Cancer and Nutrition (EPIC)* which was developed by the DIFE (German Institute of Human Nutrition) assessing physical activity in hours per week.[38]

Psychological factors: Depressive symptoms were assessed with the *Patient-Health-Questionnaire 9 (PHQ-9),* a valid, reliable self-report questionnaire consisting of 9 items on a four-point scale (0 *not at all* to 3 *nearly every day)* categorized as *mild* (10-14), *medium* (15-29) and *high* (20-27).[39]

Anxiety was assessed with the *Generalized-Anxiety-Disorder-7 (GAD-7)*, a valid, reliable self-report 7-item questionnaire assessing symptoms on a four-point scale (0 *not at all* to 3 *nearly every day)* and cut-off points classifying *mild* (5-9), *moderate* (10-14) and *severe* (15-21) anxiety.[40]

Adverse Childhood Experiences were assessed using the same named 10-item questionnaire (ACE) for five types of childhood traumatization (e.g. *sexual* and *physical abuse*) with a dichotomous response format (no/yes) and a sum score by summing all ACEs.[41]

Data analysis

Statistical analyses were carried out using SPSS version 27. Missing data in the self-report scales (PHQ-15, PHQ-9, GAD7 and EQ5D), ranging from 7.6 to 12.8% was imputed using the expectation-maximization-algorithm if at least one item was completed. Missing

educational status variables (5.8%) were replaced with a medium education level. Missing data in the other variables ranged from 3.1% (haemoglobin) to 33.6% (expectation of deterioration) which were not imputed. Because of similar group sizes of the CKD and CHD group, only the healthy controls were matched.

To analyse biopsychosocial correlates of somatic symptom burden in CKD a stepwise multiple linear regression model with four steps was conducted. Variables were included in the model in the following order: 1) sociodemographic factors (age, sex and education), 2) biomedical factors (eGFR, body mass index (BMI), coronary heart disease, arterial hypertension, diabetes mellitus, dyslipidaemia and medication), 3) health-related factors (physical activity, smoking behaviour, general health status, proneness to illness, expectancy of deterioration and sum of physician visits per year), 4) psychological factors (depressive symptoms, anxiety and adverse childhood experiences). The same regression model was applied to examine the influence of these factors on QoL in CKD. Analogous regression models were calculated in the CHD and the healthy control group to compare correlates across these groups. Odds ratios were calculated with logistic regression models to compare the existence of single symptoms of the PHQ-15 in all groups. To examine potential differences of biopsychosocial correlates of somatic symptom burden within the CKD group, ANOVAs and Chi-Square tests were then calculated.

Results:

Sample characteristics

The CKD cohort included 582 individuals and 618 individuals had coronary heart disease. The healthy control group constituted of 582 individuals. The study population was predominantly white. Table 1 provides an overview of the demographic and clinical characteristics of the overall HCHS cohort and the three subgroups. Participants with CKD and the healthy control sample were significantly older than participants with CHD ($F = 28.12$, $p < .001$). The percentage of women was higher in the CKD and healthy control group compared to the CHD group ($\chi^2 = 72.80$, $p < .001$). Scores of the psychological assessments were higher in the CHD group for general symptom burden ($F = 9.75$, $p < .001$), depressive symptoms ($F = 8.16$, $p < .001$), and adverse childhood experiences ($F = 4.85$, $p = .008$) when comparing to healthy controls. Anxiety scores were the highest in the CHD group ($F = 4.86$, $p = .008$). In turn, the healthy control group scored highest on the QoL scale ($F = 14.65$, $p < .001$).

Insert Table 1 here

Biopsychosocial correlates of somatic symptom burden

In the CKD group, lower eGFR ($r = -.161$, $p < .001$) and a higher BMI ($r = .116$, $p = .01$) were correlated with higher symptom burden. Depressive symptoms ($r = .675$, $p < .001$), anxiety ($r = .543$, $p < .001$), adverse childhood experiences ($r = .271$, $p < .001$), QoL ($r = -.538$, $p < .001$) as well as the sum of physician visits per year ($r = .245$, $p < .001$) correlated significantly with somatic symptom burden (see supplemental table S1 for all bivariate correlations with symptom burden and QoL).

Analysing biopsychosocial correlates of somatic symptom burden, a stepwise multiple linear regression model was calculated in the CKD sample (Table 2). Female sex was

associated with higher somatic symptom burden (β = .143, $p < .001$). Only comorbid coronary heart disease as biological factor was associated with higher symptom burden (β = .113, $p = .005$), while eGFR was not (β = -.053, $p = .15$). Self-reported poor general health status (β = .201, $p < .001$) was an associated health-related factor. Depressive symptoms were associated with high somatic symptom burden (β = .469, $p < .001$). The final regression model explained 57.2% of the variance in somatic symptom burden.

Insert Table 2 here

Biopsychosocial correlates of quality of life

Higher somatic symptom burden correlated with lower QoL in the CKD group ($r = -.538$, $p < .001$). Additionally, all except one single item of the PHQ-15 correlated significantly and negatively with QoL (S2). In the multivariable regression model, male sex (β = -.089, $p = .05$), lower BMI (β = -.152, $p < .001$), better general state of health (β = -.292, $p < .001$), fewer physician visits per year (β = -.128, $p = .005$), as well as lower somatic symptom burden (β = -.244, $p < .001$) were associated with higher QoL. The final regression model explained 42.5% of the variance in QoL.

Insert Table 3 here

Comparison of biopsychosocial correlates of somatic symptom burden across CKD, CHD and healthy controls

Frequencies of individual PHQ-15 symptoms were compared between groups. Individuals with CKD and healthy controls experienced less symptoms than the CHD group. Symptom frequency differed for the following symptoms, among others: *stomach* or *chest pain*,

shortness of breath and *lack of energy* (S3). Odds ratios calculated with logistic regression models showed that *stomach complaints* as well as *cardiac symptoms* were less frequent in the CKD group compared to the CHD group.

Comparing biopsychosocial correlates of somatic symptom burden in individuals with CKD to matched healthy and somatic controls with CHD, analogous stepwise multiple linear regression models were calculated in the two control groups (table 2). Common correlates of somatic symptom burden across all three groups were higher depressive symptoms (β = .385 to .469, *p*s < .001), lower general health state (β = .117 to .201, *p*s = .006 to < .001), and partly proneness to illness (β = -.077 to -.076, *p*s = .05 to .04). Female sex was associated with higher symptom burden only in the CKD and CHD group (β = .143 and .129, *p*s < .001). Higher anxiety levels were associated with higher symptom burden in the CHD (β = .171, *p*s = .004) and the healthy control group (β = .166, *ps* .003). Unique correlates of somatic symptom burden in the CHD group were age (β = .150, *p* < .001), and sum of physician visits per year (β = .088, *p* = .01). In the healthy control group, higher eGFR (β = .080, *p* = .03) and expectancy of deterioration of health status (β = -.120, *p* = .001) were identified as unique associates of somatic symptom burden.

Comparison of sociodemographic and clinical variables across CKD stages

GFR stages showed a significant positive correlation with somatic symptom burden across stages 2 to 5 (*r* = .137, *p* = .002. Tables S4 and S5 provide an overview of social demographic and clinical variables as well as symptom frequencies across CKD stages 3a-5. Due to a little number of subjects in stage 4 and 5, stages were summarised as follows: stage 3a, stage 3b to 5. When comparing psychological assessments, the groups differed particularly in terms of somatic symptom burden and QoL. Individuals in stage 3a reported a lower symptom burden (*mean* = 5.37, *SD* = 4.19 vs. *mean* = 6.78, *SD* = 4.20, *p* = .003) and a higher quality of life (*mean* = 0.88, *SD* = 0.16 vs. *mean* = 0.84, *SD* = 0.15, *p* = .01) than individuals in stages 3b to 5.

Discussion

This study examined biopsychosocial correlates of somatic symptom burden in individuals with CKD. Explaining 57.2% of its variance, significant correlates included female sex, the comorbid existence of coronary heart disease, subjectively perceived lower general health status and higher depressive symptoms.

This is consistent with existing research, identifying female sex as risk factor for PSS across diseases[42,43], including CKD.[7] In line with a recent study, the presence of coronary heart disease seemed to explain more of the symptom burden than kidney function.[7] Possible reasons might be that cardiovascular complications are closely linked to CKD and are considered one of the main causes of death in individuals with CKD.[44] As in this study, patients with CHD generally report a high symptom burden.[10]

Although associated bivariately, the eGFR was not associated with higher somatic symptom burden in the multivariable regression model, a finding supported by recent research showing that eGFR was only associated with individual symptoms but not overall symptom burden.[7] Our data further confirmed that somatic symptom burden has a strong impact on QoL [45,46] by finding a negative correlation between QoL and high symptom burden (see S1). QoL has been identified as associative factor of symptom burden in CKD before, especially in end-stage kidney disease.[8,15,47] Even if CKD is considered asymptomatic until advanced stages in past studies, patients in this study report various symptoms such as *pain in arms, legs or joints with a frequency* of up to 64.3%.[7,8]

Depressive symptoms, anxiety, and adverse childhood experiences were univariately correlated with somatic symptom burden and QoL. However, depressive symptoms emerged as the only significant psychological correlate in the regression model, even if all factors contributed to symptom persistence in past studies.[1,2,15-17].

We further aimed to compare correlates of somatic symptom burden in CKD with CHD and healthy controls. Common correlates across all three groups included higher depressive

symptoms and lower general health status. Surprisingly, anxiety did not seem to play a role in somatic symptom burden in CKD, but it appeared to be an important correlate for higher symptom burden in both of the control groups. One possible explanation could be that anxiety is more common in patients with CHD when comparing to the general population, and anxiety is a symptom genuinely associated with cardiac conditions.[48] Considering the general symptom burden and single symptoms of the PHQ-15, the CHD group showed the highest values in our sample. This could be due to the aforementioned general symptom burden of this patient group.[10]

Similar risk and protective factors for somatic symptom distress in the three groups were found, while some variables were specific correlates in only one group. Putting this into perspective in the biopsychosocial model of PSS, it is in line with broad evidence both in CKD and in other chronic conditions, as there are disease-overarching (e.g. female sex, depression) as well as disease-specific correlates (e.g. kidney function) with somatic symptom burden.[1,2,15-17] The relevance of depression and anxiety as risk factors for PSS have broadly been shown in previous research[2,13,14], and were confirmed in our analysis.

Thus, the results support a disease-overarching concept of PSS, stressing the important observation that - across all fields of medicine - symptoms can be the primary burden for patients.[1] The complete proposed biopsychosocial model cannot be tested within the limited set of variables assessed in the HCHS. Other relevant psychosocial factors not assessed here include patients' symptom and treatment expectations and experiences, cognitive-perceptual and emotional mechanisms such as catastrophizing, somatosensory amplification and emotion regulations deficits.[1,4] Novel predictive processing models interpret symptoms as imprecise representations of bodily states, often more shaped by priors (e.g. previous symptom experience) than by actual somatosensory input.[2] Crucially, these overarching mechanisms provide a convincing basis for a mechanism-driven, transdiagnostic, symptom-centered treatment approach. They should therefore be systematically integrated into the treatment and into a comprehensive biopsychosocial model of CKD.

While the HCHS provides a large representative data pool analysing biopsychosocial correlates of somatic symptom burden and allows for a comparison of CKD with another symptomatic disease (CHD) and a healthy control group, several limitations need to be considered: The cross-sectional design of the analysis does not allow for causal inferences. Only general symptoms were assessed, while CKD-specific symptom questionnaires such as the *Kidney Disease Quality of Life Instrument* (KDQOL)[49] or the *Chronic Kidney Disease Symptom Burden Index* (CKD-SBI)[50] would have provided more information on CKD-specific symptom burden. Unfortunately, CKD-specific questionnaires were not assessed as the HCHS study has agreed on a generic core set of questionnaires. Due to a limited number of correlates, other health-related and psychosocial factors such as illness perceptions or negative affectivity were not analysed in this study, which were identified as predictors of non-adherence, depression, morbidity and mortality in patients with CKD in former research.[19,23-25] Due to several single missing values in the sociodemographic data and scales, our sample for the regression analysis was reduced, limiting result validity. Another limitation was the small number of individuals with advanced CKD.

In conclusion, our study shows that symptom burden is only marginally related to kidney function in individuals with CKD, while other biopsychosocial factors such as comorbid cardiac disease and depressive symptoms play a more important role. More research on influencing factors and their underlying aetiology of PSS in CKD is necessary. To gain deeper insights into all aspects of symptom burden in CKD, it is necessary to consider a biopsychosocial model of symptom burden in CKD establishing interdisciplinary treatment approaches for PSS in CKD. As recommended in the KDIGO guidelines[29] a more interdisciplinary care in the treatment of CKD in future is postulated. This means that in addition to nephrologists or other specialists, nutritionists and psychologists should be more involved in the treatment improving symptom assessment and management.[27] The SOMA.CK study is investigating biopsychosocial predictors of symptom burden in non-dialysis CKD, aiming to identify modifiable factors and to form future interventions to reduce symptom burden, emphasizing the importance of a biopsychosocial model to better understand and influence treatment outcomes.[4]

Funding

Financial disclosures and funding are submitted in separate documents as recommended by ICMJE.

Acknowledgements

We are grateful for the HCHS team for their support with the data. We thank the involved student research assistants from the Medical School Hamburg. During the preparation of this work the authors used DEEPL in the writing process for better readability. After using this tool, the authors reviewed and edited the content as needed and take full responsibility for the content of the publication.

CRediT authorship contribution statement

Birte Jessen: conceptualization, methodology, formal analysis, writing (original draft & review and editing). **Meike Shedden-Mora:** conceptualization, methodology, formal analysis, writing (original draft & review and editing), supervision. **Tobias B. Huber:** conceptualization, writing (review & editing), methodology, supervision. **Christian Schmidt-Lauber:** writing (review & editing), methodology, supervision. **Bernd Löwe:** conceptualization, writing (review & editing), methodology. **Raphael Twerenbold:** writing (review & editing). **Martin Härter:** writing (review & editing). **Volker Harth:** writing (review & editing). **Hanno Hoven:** writing (review & editing).

Data sharing statement

Data will be shared upon reasonable request to the corresponding author. Data-sharing is subject to the approval of the steering committee of the Hamburg City Health Study.

Conflict of interest statement

The authors do not have a conflict of interest to disclose.

Supplemental material

Supplemental material is available online at …

References

1. Löwe B, Andresen V, Van den Bergh O, et al. Persistent SOMAtic symptoms ACROSS diseases - from risk factors to modification: scientific framework and overarching protocol of the interdisciplinary SOMACROSS research unit (RU 5211). *BMJ Open*. Jan 21 2022;12(1):e057596. doi:10.1136/bmjopen-2021-057596

2. Löwe B, Toussaint A, Rosmalen JGM, et al. Persistent physical symptoms: definition, genesis, and management. *The Lancet*. Jun 15 2024;403(10444):2649-2662. doi:10.1016/S0140-6736(24)00623-8

3. Hinz A, Ernst J, Glaesmer H, et al. Frequency of somatic symptoms in the general population: Normative values for the Patient Health Questionnaire-15 (PHQ-15). *J Psychosom Res*. May 2017;96:27-31. doi:10.1016/j.jpsychores.2016.12.017

4. Shedden-Mora MC, Jessen B, Schmidt-Lauber C, et al. Predictors of somatic symptom persistence in patients with chronic kidney disease (SOMA.CK): study protocol for a mixed-methods cohort study. *BMJ Open*. Nov 17 2022;12(11):e067821. doi:10.1136/bmjopen-2022-067821

5. Brown SA, Tyrer FC, Clarke AL, et al. Symptom burden in patients with chronic kidney disease not requiring renal replacement therapy. *Clinical Kidney Journal*. Dec 2017;10(6):788-796. doi:10.1093/ckj/sfx057

6. de Goeij MC, Ocak G, Rotmans JI, Eijgenraam JW, Dekker FW, Halbesma N. Course of symptoms and health-related quality of life during specialized pre-dialysis care. *PLoS One*. 2014;9(4):e93069. doi:10.1371/journal.pone.0093069

7. Speyer E, Tu C, Zee J, et al. Symptom Burden and Its Impact on Quality of Life in Patients With Moderate to Severe CKD: The International Chronic Kidney Disease Outcomes and Practice Patterns Study (CKDopps). *Am J Kidney Dis*. Aug 6 2024;doi:10.1053/j.ajkd.2024.06.011

8. Fletcher BR, Damery S, Aiyegbusi OL, et al. Symptom burden and health-related quality of life in chronic kidney disease: A global systematic review and meta-analysis. *PLoS Medicine*. Apr 2022;19(4):e1003954. doi:10.1371/journal.pmed.1003954

9. Wilkinson TJ, Nixon DGD, Palmer J, Lightfoot CJ, Smith AC. Differences in physical symptoms between those with and without kidney disease: a comparative study across disease stages in a UK population. *BMC Nephrol*. Apr 22 2021;22(1):147. doi:10.1186/s12882-021-02355-5

10. Kohlmann S, Gierk B, Hümmelgen M, Blankenberg S, Löwe B. Somatic Symptoms in Patients With Coronary Heart Disease: Prevalence, Risk Factors, and Quality of Life. *JAMA Intern Med*. Aug 12 2013;173(15):1469-71. doi:doi:10.1001/jamainternmed.2013.6835.

11. Jhamb M, Abdel-Kader K, Yabes J, et al. Comparison of fatigue, pain, and depression in patients with advanced kidney disease and cancer - symptom burden and clusters. *J Pain Symptom Manage*. Mar 2019;57(3):566-575 e3. doi:10.1016/j.jpainsymman.2018.12.006

12. Flythe JE, Karlsson N, Sundgren A, et al. Development of a preliminary conceptual model of the patient experience of chronic kidney disease: a targeted literature review and analysis. *BMC Nephrol*. Jun 23 2021;22(1):233. doi:10.1186/s12882-021-02440-9

13. Joustra ML, Janssens KA, Bultmann U, Rosmalen JG. Functional limitations in functional somatic syndromes and well-defined medical diseases. Results from the general population cohort LifeLines. *J Psychosom Res*. Aug 2015;79(2):94-9. doi:10.1016/j.jpsychores.2015.05.004

14. Henningsen P, Zipfel S, Sattel H, Creed F. Management of functional somatic syndromes and bodily distress. *Psychotherapy and Psychosomatics*. Jan 6 2018;87(1):12-31. doi:10.1159/000484413

15. Abdel-Kader K, Unruh ML, Weisbord SD. Symptom burden, depression, and quality of life in chronic and end-stage kidney disease. *Clinical Journal of the American Society of Nephrology*. Jun 2009;4(6):1057-64. doi:10.2215/cjn.00430109

16. Liu M, Zhang Y, Yang S, et al. Bidirectional relations between depression symptoms and chronic kidney disease. *J Affect Disord*. Aug 15 2022;311:224-230. doi:10.1016/j.jad.2022.05.104

17. Bahall M, Legall G, Lalla C. Depression among patients with chronic kidney disease, associated factors, and predictors: a cross-sectional study. *BMC Psychiatry*. Oct 10 2023;23(1):733. doi:10.1186/s12888-023-05249-y

18. Ozieh MN, Garacci E, Campbell JA, Walker RJ, Egede LE. Adverse Childhood Experiences and Decreased Renal Function: Impact on All-Cause Mortality in U.S. Adults. *Am J Prev Med*. Aug 2020;59(2):e49-e57. doi:10.1016/j.amepre.2020.04.005

19. Clarke AL, Yates T, Smith AC, Chilcot J. Patient's perceptions of chronic kidney disease and their association with psychosocial and clinical outcomes: a narrative review. *Clin Kidney J*. Jun 2016;9(3):494-502. doi:10.1093/ckj/sfw014

20. Hughes K, Bellis MA, Hardcastle KA, et al. The effect of multiple adverse childhood experiences on health: a systematic review and meta-analysis. *Lancet Public Health*. Aug 2017;2(8):e356-e366. doi:10.1016/S2468-2667(17)30118-4

21. Cay M, Gonzalez-Heydrich J, Teicher MH, et al. Childhood maltreatment and its role in the development of pain and psychopathology. *Lancet Child Adolesc Health*. Mar 2022;6(3):195-206. doi:10.1016/S2352-4642(21)00339-4

22. Zhang K, Wang Y, Sun Y, Gao L, Lu Y, Wang N. Self-reported childhood adversity, unhealthy lifestyle and risk of new-onset chronic kidney disease in later life: A prospective cohort study. *Soc Sci Med*. Jan 2024;341:116510. doi:10.1016/j.socscimed.2023.116510

23. Zelle DM, Klaassen G, van Adrichem E, Bakker SJ, Corpeleijn E, Navis G. Physical inactivity: a risk factor and target for intervention in renal care. *Nat Rev Nephrol*. Mar 2017;13(3):152-168. doi:10.1038/nrneph.2016.187

24. Magadi W, Lightfoot CJ, Memory KE, et al. Patient activation and its association with symptom burden and quality of life across the spectrum of chronic kidney disease stages in England. *BMC Nephrol*. Jan 26 2022;23(1):45. doi:10.1186/s12882-022-02679-w

25. Moeinzadeh F, Babahajiani M, Seirafian S, et al. Assessing physical inactivity as a risk factor for chronic kidney diseases in Iranian population. *BMJ Open*. Jun 7 2023;13(6):e070360. doi:10.1136/bmjopen-2022-070360

26. Henningsen P, Gündel H, Kop WJ, et al. Persistent physical symptoms as perceptual dysregulation: A neuropsychobehavioral model and its clinical implications. *Psychosomatic Medicine*. Jun 2018;80(5):422-431. doi:10.1097/PSY.0000000000000588

27. Shedden-Mora M, Jessen B, Huber TB. Why Symptom Burden in Non-Dialysis CKD Matters. *Am J Kidney Dis*. Oct 9 2024;doi:10.1053/j.ajkd.2024.07.005

28. Jagodzinski A, Johansen C, Koch-Gromus U, et al. Rationale and Design of the Hamburg City Health Study. *Eur J Epidemiol*. Feb 2020;35(2):169-181. doi:10.1007/s10654-019-00577-4

29. KDIGO. KDIGO 2024 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease. *Kidney International*. 2024;105(4)doi:10.1016/s0085-2538(24)00110-8

30. Levey AS, Stevens LA. Estimating GFR using the CKD Epidemiology Collaboration (CKD-EPI) creatinine equation: more accurate GFR estimates, lower CKD prevalence estimates, and better risk predictions. *Am J Kidney Dis*. Apr 2010;55(4):622-7. doi:10.1053/j.ajkd.2010.02.337

31. Schmidt-Lauber C, Hanzelmann S, Schunk S, et al. Kidney outcome after mild to moderate COVID-19. *Nephrol Dial Transplant*. Aug 31 2023;38(9):2031-2040. doi:10.1093/ndt/gfad008

32. Kroenke K, Spitzer RL, Williams JBW, DSW. The PHQ-15: Validity of a New Measure for Evaluation the Severity of Somatic Symptoms. *Psychosomatic Medicine*. 2002;64:258-266. doi:10.1097/00006842-200203000-00008

33. Zijlema WL, Stolk RP, Löwe B, et al. How to assess common somatic symptoms in large-scale studies: a systematic review of questionnaires. *J Psychosom Res*. Jun 2013;74(6):459-68. doi:10.1016/j.jpsychores.2013.03.093

34. Feng YS, Kohlmann T, Janssen MF, Buchholz I. Psychometric properties of the EQ-5D-5L: a systematic review of the literature. *Qual Life Res*. Mar 2021;30(3):647-673. doi:10.1007/s11136-020-02688-y

35. Eurostat. International Standard Classification of Education (ISCED) - Statistics Explained. 09/08/2023 2023;

36. Petersen EL, Gossling A, Adam G, et al. Multi-organ assessment in mainly non-hospitalized individuals after SARS-CoV-2 infection: The Hamburg City Health Study COVID programme. *Eur Heart J*. Mar 14 2022;43(11):1124-1137. doi:10.1093/eurheartj/ehab914

37. Scheidt-Nave C, Kamtsiuris P, Gößwald A, et al. German health interview and examination survey for adults (DEGS) - design, objectives and implementation of the first data collection wave. *BMC Public Health*. 2012;

38. Wareham NJ, Jakes RW, Rennie KL, Mitchell J, Hennings S, Day NE. dity and repeatability of the EPIC-Norfolk Physical Activity Questionnaire. *International Journal of Epidemiology*. 2002;31(1):168-174. doi:https://doi.org/10.1093/ije/31.1.168

39. Kocalevent RD, Hinz A, Brahler E. Standardization of the depression screener patient health questionnaire (PHQ-9) in the general population. *Gen Hosp Psychiatry*. Sep-Oct 2013;35(5):551-5. doi:10.1016/j.genhosppsych.2013.04.006

40. Jordan P, Shedden-Mora MC, Löwe B. Psychometric analysis of the Generalized Anxiety Disorder scale (GAD-7) in primary care using modern item response theory. *PLoS One*. 2017;12(8):e0182162. doi:10.1371/journal.pone.0182162

41. Boullier M, Blair M. Adverse childhood experiences. *Paediatrics and Child Health*. 2018;28(3):132-137. doi:10.1016/j.paed.2017.12.008

42. Ballering AV, Bonvanie IJ, Olde Hartman TC, Monden R, Rosmalen JGM. Gender and sex independently associate with common somatic symptoms and lifetime prevalence of chronic disease. *Soc Sci Med*. May 2020;253:112968. doi:10.1016/j.socscimed.2020.112968

43. Ballering AV, Wardenaar KJ, Olde Hartman TC, Rosmalen JGM. Female sex and femininity independently associate with common somatic symptom trajectories. *Psychol Med*. Aug 2022;52(11):2144-2154. doi:10.1017/S0033291720004043

44. Mitsnefes MM. Cardiovascular complications of pediatric chronic kidney disease. *Pediatr Nephrol*. Jan 2008;23(1):27-39. doi:10.1007/s00467-006-0359-0

45. Elorza CLC, Santos Junior AD, Celeri E. Quality of life, depression and anxiety in children and adolescents with CKD and their primary caregivers. *J Bras Nefrol*. Jul-Sep 2023;45(3):335-343. doi:10.1590/2175-8239-JBN-2022-0036en

46. Mohamed NA, Eraslan A, Kose S. The impact of anxiety and depression on the quality of life of hemodialysis patients in a sample from Somalia. *BMC Psychiatry*. Nov 10 2023;23(1):825. doi:10.1186/s12888-023-05312-8

47. Pugh-Clarke K, Read SC, Sim J. Symptom experience in non-dialysis-dependent chronic kidney disease: A qualitative descriptive study. *J Ren Care*. Dec 2017;43(4):197-208. doi:10.1111/jorc.12208

48. Clarke DM, Currie KC. Depression, anxiety and their relationship with chronic diseases: a review of the epidemiology, risk and treatment evidence. *Med J Aust*. Apr 6 2009;190(S7):S54-60. doi:10.5694/j.1326-5377.2009.tb02471.x

49. Ricardo AC, Hacker E, Lora CM, et al. Validation of the kidney disease quality of life short form 36 (KDQOL-36™) US Spanish and English versions in a cohort of hispanics with chronic kidney disease. *Ethnicity & disease*. 2013;23(2):202.

50. Aiyegbusi OL, Kyte D, Cockwell P, et al. Measurement properties of patient-reported outcome measures (PROMs) used in adult patients with chronic kidney disease: A systematic review. *PLoS One*. 2017;12(6):e0179733. doi:10.1371/journal.pone.0179733

Table 1: ***Demographic and clinical characteristics of participants***

Characteristic	cohort of 10.000	CKD cohort[a]	CHD control group[b]	healthy control group[c]	comparison
n	10.000	582	618	582	
Sociodemographic variables					
Age *mean* ± *SD*; *(range)*	62.37 ± 8.45 (46-78)	69.58 ± 6.37 (47-78)	67.13 ± 6.92 (47-78)	69.58 ± 6.37 (47-78)	*t* = 6.39, ***p* < .001 (a > b)**
Sex, female n (%)	5108 (51.1%)	260 (44.7%)	149 (24.1%)	260 (44.7%)	χ^2 = 56.41, ***p* < .001 (a > b)**
Education n (%)					
Low	466 (4.7%)	42 (7.2.0%)	35 (5.7%)	42 (7.2%)	
Medium	4721 (47.2%)	293 (50.3%)	293 (47.4%)	298 (51.2%)	
High	4232 (42.3%)	196 (33.7%)	250 (40.5%)	196 (33.7%)	χ^2 = 5.19, *p* = .08
Ethnicity					-
White	9802 (98.0%)	572 (98.3%)	611 (98.9%)	573 (98.5%)	
Hispanic	35 (0.4%)	2 (0.3%)	1 (0.2%)	1 (0.2%)	
Asian	57 (0.6%)	0 (0.0%)	1 (0.2%)	3 (0.5%)	
Black	36 (0.4%)	1 (0.2%)	1 (0.2%)	2 (0.3%)	
Other	40 (0.4%)	2 (0.3%)	3 (0.5%)	2 (0.3%)	
Health-related assessments					
Physical activity in h/week *mean* ± *SD*; *(range)*	2.61 ± 3.00 (0.00-20.00)	2.30 ± 3.34 (0.00-20.00)	2.55 ± 3.11 (0.00-20.00)	2.76 ± 3.34 (0.00-20.00)	*F* = 2.44, *p* = .09
Current smoker n (%)	1978 (19.8%)	85 (14.6%)	113 (18.3%)	86 (14.8%)	χ^2 = 3.92, *p* = .141
eGFR mean ± SD; (*range*)	84 ± 14 (6-127)	52 ± 8 (7-59)	81 ± 11 (60-111)	81 ± 11 (60-112)	*F* = 1627.23, ***p* = .000 (a < b, c)**
Haemoglobin (g/dl) *mean* ± *SD;* (*range*)	14.34 ± 1.14 (8.3-18.9)	14.12 ± 1.39 (9.5-18.7)	14.60 ± 1.20 (9.9-18.0)	14.43 ± 1.19 (9.0-18.1)	*F* = 21.55, ***p* < .001 (a < b, c)**
hs CRP (mg/dl) *mean* ± *SD; (range*)	0.24 ± 0.44 (0.01-11.70)	0.31 ± 0.46 (0.01-6.25)	0.24 ± 0.38 (0.01-4.35)	0.27 ± 0.47 (0.01-5.47)	*F* = 3.90, ***p* = .02 (a > b)**
BMI (kg/m²) *mean* ± *SD;* (*range*)	26.76 ± 4.69 (15.59-61.63)	28.75 ± 5.34 (18.31-48.51)	28.06 ± 4.61 (16.84-61.63)	26.94 ± 4.44 (16.91-45.59)	*F* = 19.90, ***p* < .001 (a, b > c; b > c)**
Systolic blood pressure (mmHg) *mean* ± *SD;* (*range*)	138.84 ± 19.36 (65.0-249.5)	143.13 ± 21.14 (92.0-249.5)	141.20 ± 18.25 (87.5-206.5)	144.48 ± 20.79 (65.0-223.0)	*F* = 3.90, ***p* = .02 (b < c)**
Diastolic blood pressure (mmHg) *mean* ± *SD*; (*range*)	82.09 ± 10.04 (41.5-131.0)	80.58 ± 10.96 (41.5-125.0)	80.71 ± 10.53 (49.5-112.5)	81.82 ± 10.41 (50.0-119.0)	*F* = 2.30, *p* = .101
Heart frequency (bpm) *mean* ± *SD*; (*range*)	69.70 ± 11.10 (29.0-129.0)	70.01 ± 12.02 (34.0-119.5)	68.12 ± 11.55 (34.0-107.0)	70.45± 11.77 (35.0-117.0)	*F* = 6.39, ***p* = .002 (a > b, b < c)**
Current medication n (%)	7539 (75.4%)	508 (87.3%)	579 (93.7%)	470 (80.8%)	χ^2 = 51.45, ***p* < .001 (a < b; a, b > c)**
Diabetes mellitus n (%)	794 (7.9%)	126 (21.6%)	99 (16.0%)	59 (10.1%)	X^2 = 28.17, ***p* < .001 (a > b, c; b > c)**

Coronary heart disease n (%)	758 (7.6%)	109 (18.7%)	618 (100%)	-	χ^2 = 1414.44, ***p* < .001 (a < b)**
Arterial hypertension n (%)	6301 (66.0%)	507 (87.1%)	568 (91.9%)	435 (74.7%)	X^2 = 72.74, ***p* < .001 (a < b; a, b > c)**
Dyslipidaemia n (%)	2276 (22.8%)	252 (43.3%)	432 (69.9%)	159 (27.3%)	χ^2 = 218.17, ***p* < .001 (a < b; a, b > c)**
Asthma bronchiale n (%)	861 (8.6%)	47 (8.1%)	54 (8.7%)	51 (8.8%)	χ^2 = 0.16, *p* = .92
Chronic obstructive bronchitis n (%)	629 (6.3%)	44 (7.6%)	65 (10.5%)	39 (6.7%)	χ^2 = 5.90, *p* = .05
Cancer n (%)	1592 (15.9%)	158 (27.1%)	115 (18.6%)	113 (19.4%)	χ^2 = 16.20, ***p* < .001 (a > b, c)**
Psychological variables					
Somatic symptom burden (PHQ-15) *mean ± SD*	4.99 ± 3.99	5.63 ± 4.23	6.20 ± 4.71	5.04 ± 4.10	*F* = 9.75, ***p* < .001 (b > c)**
Low symptom burden (0-4) n (%)	4994 (49.9%)	233 (40.0%)	246 (39.8%)	295 (50.7%)	
Medium symptom burden (5-9) n (%)	2972 (29.7%)	185 (31.8%)	180 (29.1%)	170 (29.2%)	
High symptom burden (≥10) n (%)	1212 (12.1%)	95 (16.3%)	136 (22.0%)	66 (11.3%)	χ^2 = 31.23, ***p* < .001 (a, c < b)**
Depressive symptoms (PHQ-9) *mean ± SD*	3.54 ± 3.56	3.52 ± 3.49	4.01 ± 3.95	3.12 ± 3.47	*F* = 8.16, ***p* < .001 (b > c)**
Anxiety (GAD7) *mean ± SD*	2.78 ± 3.04	2.47 ± 2.90	2.94 ± 3.22	2.43 ± 2.86	*F* = 4.86, ***p* = .008 (a, c < b)**
Adverse Childhood Experience (ACE) *mean ± SD*	1.16 ± 1.63	1.10 ± 1.53	1.22 ± 1.75	0.92 ± 1.43	*F* = 4.85, ***p* = .008 (b > c)**
Quality of life (EQ5D-5L) *mean ± SD*	0.91 ± 0.13	0.87 ± 0.16	0.88 ± 0.17	0.92 ± 0.11	*F* = 14.65, ***p* < .001 (a, b < c)**
Visual analogue scale of quality of life (EQ5D-5L) *mean ± SD*	79.19 ± 15.26	72.80 ± 18.52	72.20 ± 18.85	79.02 ± 14.39	*F* = 25.33, ***p* < .001 (a, b < c)**

Note. Sample sizes across variables may differ due to missing values. Comparisons were analysed using Bonferroni post hoc tests. Bold types stand for significant values.

CKD, chronic kidney disease; CHD, coronary heart disease; eGFR, estimated glomerular filtration rate; hsCRP, highly sensitive C-reactive protein; BMI, Body-Mass-Index; PHQ-15, Patient-Health-Questionnaire-15; PHQ-9, Patient-Health-Questionnaire-9; GAD-7, Generalized-Anxiety-Disorder-7; ACE, Adverse Childhood Experiences; EQ5D-5L, European Quality of Life 5 Dimensions 5 Level Version; SD, standard deviation; t, t-value; n, number; χ^2, chi square coefficient; p, p-value; F, F-value;

Table 2: ***Correlates of somatic symptom burden in individuals with CKD, CHD and healthy controls using a stepwise multiple linear regression model***

Steps	CKD group		CHD group		healthy control group	
	Standardized beta	p-value	Standardized beta	p-value	Standardized beta	p-value
Step 1: sociodemographic factors	**(R^2= .071, p < .001; ΔR² = .079; p < .001)**		**(R^2= .057, p < .001; ΔR² = .064; p < .001)**		**(R^2 = .019, p = .019; ΔR² = .027; p = .019)**	
Age	.018	.63	**.150**	**<.001**	.074	.06
Female sex	**.143**	**<.001**	**.129**	**<.001**	.065	.09
Education	-.031	.41	.005	.89	.000	1.00
Step 2: biological factors	**(R^2 = .147, p < .001; ΔR² = .092; p < .001)**		**(R^2 = .071, p = .060; ΔR² = .027; p < .001)**		**(R^2 = .065, p < .001; ΔR² = .061; p < .001)**	
eGFR	-.053	.15	-.012	.75	**.080**	**.03**
BMI	.000	.99	.051	.16	.056	.14
Coronary heart disease	**.113**	**.005**	-	-	-	-
Arterial hypertension	.009	.82	-.005	.89	.044	.24
Diabetes mellitus	.054	.15	-.032	.36	.043	.24
Dyslipidaemia	.005	.91	-.015	.67	.011	.75
Medication	-.052	.16	-.021	.56	.020	.59
Step 3: health-related factors	**(R^2 = .374, p < .001; ΔR² = .232; p < .001)**		**(R^2 = .364, p < .001; ΔR² = .295; p < .001)**		**(R^2 = .316, p < .001; ΔR² = .257; p < .001)**	
Physical activity in h/week	-.007	.86	-.037	.28	-.028	.44
Smoking behavior	-.026	.47	.011	.76	-.049	.18
General state of health	**.201**	**<.001**	**.185**	**<.001**	**.117**	**.006**
Proneness to illness	-.065	.11	**-.076**	**.05**	**-.077**	**.04**
Expectancy of deterioration of health status	-.013	.73	-.025	.48	**-.120**	**.001**
Sum of physician visits per year	.070	.07	**.088**	**.01**	.039	.29
Step 4: psychological factors	**(R^2 = .572, p < .001; ΔR² = .192; p < .001)**		**(R^2 = .575, p < .001; ΔR² = .207; p < .001)**		**(R^2 = .582, p < .001; ΔR² = .258; p < .001)**	
Depression (PHQ-9)	**.469**	**<.001**	**.385**	**<.001**	**.459**	**<.001**
Anxiety (GAD-7)	.066	.24	**.171**	**.004**	**.166**	**.003**
Adverse Childhood Experience (ACE)	.015	.69	.067	.07	.049	.19

Note. Coefficients from the final regression model are reported in each step. Due to missing values, the following sample sizes result in the individual groups: n CKD group = 359, n CHD group = 414, n healthy control group = 363. Bold types stand for significant values.

CKD, chronic kidney disease; CHD, coronary heart disease; eGFR, estimated glomerular filtration rate; BMI, Body-Mass-Index; PHQ-9, Patient-Health-Questionnaire-9; GAD-7, Generalized-Anxiety-Disorder-7; ACE, Adverse Childhood Experiences; R^2, coefficient of determination R^2; ΔR^2, adjusted R^2; p, p-value;

Table 3: ***Correlates of quality of life in individuals with CKD using a stepwise multiple linear regression model***

Steps	Standardized beta	p-value
	(R^2 = .037, *p* = .001; ΔR² = .045, *p* = .001)	
Step 1: sociodemographic factors		
Age	-.044	.31
Sex	**-.089**	**.05**
Education	-.056	.20
	(R^2 = .113, *p* < .001; ΔR² = .093, *p* < .001)	
Step 2: biological factors		
eGFR	-.048	.25
BMI	**-.152**	**<.001**
Coronary heart disease	.029	.53
Arterial hypertension	-.045	.30
Diabetes mellitus	-.018	.68
Hyperlipoproteinemia	.019	.68
Medication	.042	.33
	(R^2 = .350, *p* < .001; ΔR² = .241, *p* < .001)	
Step 3: health-related factors		
Physical activity in h/week	-.031	.46
Smoking behaviour	-.044	.29
General state of health	**-.292**	**<.001**
Proneness to illness	-.021	.65
Expectancy of deterioration of health status	.008	.86
Sum of physician visits per year	**-.128**	**.005**
	(R^2 = .401, *p* < .001; ΔR² = .054, *p* < .001)	
Step 4: psychological factors		
Depression – PHQ-9	**-.155**	**.04**
Anxiety – GAD-7	.000	1.00
Adverse Childhood Experience - ACE	.020	.65
Step 5: somatic symptom burden	**(R^2 = .425, *p* < .001; ΔR² = .024, *p* < .001)**	
Somatic symptom burden – PHQ-15	**-.244**	**<.001**

Note: Due to missing values, the following sample size results: n = 359. Bold types stand for significant values.

CKD, chronic kidney disease; eGFR, estimated glomerular filtration rate; BMI, Body-Mass-Index; PHQ-9, Patient-Health-Questionnaire-9; GAD-7, Generalized-Anxiety-Disorder-7; ACE, Adverse Childhood Experiences; PHQ-15, Patient-Health-Questionnaire-15; R^2, coefficient of determination R^2; ΔR², adjusted R^2; p, p-value;

Supplements

Table S1: Correlations with somatic symptom burden and quality of life in individuals with CKD

Characteristic	Somatic symptom burden (PHQ-15)		Quality of life (EQ5D-5L)	
	r / T	p-value	r / T	p-value
Sociodemographic variables				
Age	-.004	.93	.012	.79
Sex*	**.186**	**<.001**	**-.160**	**<.001**
Education*	**-.156**	**<.001**	**.108**	**.004**
Biological variables				
eGFR	**-.161**	**<.001**	**.116**	**.008**
BMI	**.116**	**.01**	**-.209**	**<.001**
Coronary heart disease*	**.139**	**<.001**	**-.115**	**.002**
Arterial hypertension*	.023	.54	**-.130**	**<.001**
Diabetes mellitus*	.087	.02	**-.138**	**<.001**
Hyperlipoproteinemia*	.049	.20	**-.077**	**.04**
Medication*	.072	.06	-.066	.08
Health-related variables				
Physical activity in h/week	-.083	.08	.060	.19
Smoking behaviour*	.033	.39	-.053	.16
General state of health	**.491**	**<.001**	**-.545**	**<.001**
Proneness to illness	**-.333**	**<.001**	**.250**	**<.001**
Expectancy of deterioration of health status	**-.169**	**<.001**	**.125**	**.005**
Sum of physician visits per year	**.245**	**<.001**	**-.259**	**<.001**
Quality of life – EQ5D-5L	**-.538**	**<.001**	-	-
Psychological variables				
Depression - PHQ-9	**.675**	**<.001**	**-.513**	**<.001**
Anxiety – GAD-7	**.543**	**<.001**	**-.389**	**<.001**
Adverse childhood experiences – ACE	**.271**	**<.001**	**-.163**	**<.001**

Note. Categorial variables were calculated with non-parametric correlations. Sample sizes across variables may differ due to missing values.

*Categorial variables.

CKD, chronic kidney disease; PHQ-15, Patient-Health-Questionnaire-15; EQ5D-5L, European Quality of Life 5 Dimensions 5 Level Version; eGFR, estimated glomerular filtration rate; BMI, Body-Mass-Index; PHQ-9, Patient-Health-Questionnaire-9; GAD-7, Generalized-Anxiety-Disorder-7; ACE, Adverse Childhood Experiences; r, Pearson correlation coefficient; T, Kendall's tau;

Table S2: Correlations with quality of life and single somatic symptoms in individuals with CKD

Characteristic	**Quality of life (EQ5D-5L)**	
PHQ-15 variables		
	r	p-value
Stomach pain	**-.145**	**.001**
Back pain	**-.455**	**<.001**
Pain in your arms, legs, or joints (knee, hips, etc.)	**-.546**	**<.001**
Menstrual cramps or other problems with your periods (women only)	-.080	.07
Pain or problems during sexual intercourse	**-.136**	**.002**
Headaches	**-.263**	**<.001**
Chest pain	**-.265**	**<.001**
Dizziness	**-.275**	**<.001**
Fainting spells	**-.176**	**<.001**
Feeling your heart pound or race	**-.165**	**<.001**
Shortness of breath	**-.352**	**<.001**
Constipation, loose bowels, or diarrhoea	**-.179**	**<.001**
Nausea, gas, or indigestion	**-.212**	**<.001**
Feeling tired or having low energy	**-.420**	**<.001**
Trouble sleeping	**-.266**	**<.001**

Note: Sample sizes across variables may differ due to missing values.

CKD, chronic kidney disease; PHQ-15, Patient-Health-Questionnaire-15; EQ5D-5L, European Quality of Life 5 Dimensions 5 Level Version; r, Pearson correlation coefficient;

Table S3: Symptom amount measured with PHQ-15 – comparison of groups

Characteristic	**cohort of 10.000**	**CKD group[a]**	**CHD group[b]**	**healthy control group[c]**	**comparison**	**CKD vs. CHD OR, 95% CI**	**CKD vs. HC OR, 95% CI**
n	10.000	582	618	582			
PHQ-15 variables							
Stomach Pain n (%)	1508 (15.1%)	73 (12.5%)	112 (18.1%)	98 (16.8%)	χ^2 = 7.58, ***p* =.02 (a < b, c)**	0.65 [.471, .892] **(a < b)**	0.71 [.510, .983] **(a < c)**
Back Pain n (%)	4832 (48.3%)	304 (52.2%)	323 (52.3%)	302 (51.9%)	χ^2 = 0.02, *p* = .99	1.00 [.796, 1.253]	1.01 [.806, 1.276]
Pain in your arms, legs, or joints (knee, hips, etc.) n (%)	5328 (53.3%)	360 (61.9%)	372 (60.2%)	336 (57.7%)	χ^2 = 2.09, *p* = .35	1.07 [.850, 1.353]	1.19 [.939, 1.501]
Menstrual cramps or other problems with your periods (women only) n (%)	283 (2.8%)	4 (0.7%)	2 (0.3%)	6 (1.0%)	χ^2 =2.24, *p* = .33	2.13 [.389, 11.68]	0.66 [.186, 2.367]
Pain or problems during sexual intercourse n (%)	1567 (15.7%)	127 (21.8%)	149 (24.1%)	107 (18.4%)	χ^2 = 5.88, ***p* = .05 (b > c)**	0.88 [.671, 1.150]	1.24 [.929, 1.652]
Headaches n (%)	2733 (27.3%)	118 (20.3%)	141 (22.8%)	124 (21.3%)	χ^2 = 1.16, *p* = .56	0.86 [.653, 1.134]	0.94 [.708, 1.247]
Chest pain n (%)	1064 (10.6%)	67 (11.5%)	145 (23.5%)	55 (9.5%)	χ^2 = 54.38, ***p* < .001 (a < b; b > c)**	0.43 [.310, .582] **(a < b)**	1.25 [.855, 1.817]
Dizziness n (%)	2079 (20.8%)	155 (26.6%)	179 (29.0%)	146 (25.1%)	X^2 = 2.33, *p* = .31	0.89 [.691, 1.147]	1.08 [.834, 1.409]
Fainting spells n (%)	128 (1.3%)	9 (1.5%)	11 (1.8%)	14 (2.4%)	χ^2 = 1.23, *p* = .54	0.87 [.357, 2.107]	0.64 [.274, 1.484]
Feeling your heart pound or race n (%)	1701 (17%)	114 (19.6%)	183 (29.6%)	96 (16.5%)	χ^2 = 33.06, ***p* < .001 (a < b; b > c)**	0.58 [.443, .757] **(a < b)**	1.23 [.914, 1.664]
Shortness of breath n (%)	2518 (25.2%)	210 (36.1%)	251 (40.6%)	157 (27.0%)	χ^2 = 25.36, ***p* < .001 (a, b > c)**	0.83 [.654, 1.042]	1.53 [1.191, 1.961] **(a > c)**
Constipation, loose bowels, or diarrhoea n (%)	2760 (27.6%)	154 (26.5%)	205 (33.2%)	163 (28.0%)	χ^2 = 7.21, ***p* = .03 (a < b)**	0.73 [.565, .930] **(a < b)**	0.93 [.714, 1.197]
Nausea, gas, or indigestion n (%)	3103 (31%)	158 (27.1%)	219 (35.4%)	177 (30.4%)	χ^2 = 9.80, ***p* = .007 (a < b)**	0.68 [.531, .868] **(a < b)**	0.85 [.661, 1.099]
Feeling tired or having low energy n (%)	4601 (46%)	258 (44.3%)	283 (45.8%)	233 (40.0%)	χ^2 = 4.33, *p* =.12 **(b > c)**	0.94 [.751, 1.183]	1.19 [.945, 1.506]
Trouble sleeping n (%)	4800 (48%)	270 (46.4%)	307 (49.7%)	264 (45.4%)	χ^2 = 2.46, *p* = .29	0.88 [.699, 1.100]	1.04 [.828, 1.313]
Symptom amount (*mean* ± *SD*)	4.27 ± 3.02	4.69 ± 3.11	5.19 ± 3.50	4.32 ± 3.08	*F* = 9.99, ***p* < .001 (a < b; b > c)**	-	-

Note: Sample sizes across variables may differ due to missing values. Bold types stand for significant values.

PHQ-15, Patient-Health-Questionnaire-15; CKD, chronic kidney disease; CHD, coronary heart disease; OR, Odds ratio; CI, confidence interval; n; number; χ^2, chi-square coefficient; p, p-value; F, F-value;

Table S4: Comparison of social demographic and clinical variables across CKD stages

Characteristic	**Stage 3a (45-59)[a]**	**Stage 3b, 4 & 5 (44-<15)[b]**	**comparison**
n	467	115	
Sociodemographic variables			
Age *mean ± SD (range)*	69.22 ± 6.54 (47-78)	71.03 ± 5.40 (48-78)	95% CI [-2.96, -0.64], *t*(204.55) = -3.06, ***p* = .002 (b > a)**
Sex = female in n (%)	207 (44.3%)	53 (46.1%)	X^2 = 0.12, *p* = .73
Education n (%)			
Low	34 (7.3%)	8 (7.0%)	
Medium	238 (51.0%)	55 (47.8%)	
High	161 (34.5%)	35 (30.4%)	χ^2 = 0.08, *p* = .96
Biological variables			
Physical activity in h/week *mean ± SD (range)*	2.42 ± 3.38 (0.00-20.00)	1.78 ± 3.10 (0.00-20.00)	95% CI [-0.13, 1.41], *t*(475) = -1.633, ***p* = .10**
Current smoker n (%)	61 (13.1%)	24 (20.9%)	χ^2 = 4.31, ***p* = .04 (a < b)**
eGFR *mean ± SD (range)*	55 ± 4 (45-59)	39 ± 6 (7-44)	95% CI [15.83, 18.62], *t*(132.08) = 24.42, ***p* < .001 (a > b)**
Potassium (mmol/l) *mean ± SD (range)*	3.97 ± 0.34 (2.3-5.1)	4.18 ± 0.49 (2.7-6.1)	95% CI [-0.31, -0.12], *t*(141.60) = -4.42, ***p* < .001 (a < b)**
Haemoglobin (g/dl) *mean ± SD (range)*	14.29 ± 1.28 (9.5-18.0)	13.46 ± 1.60 (9.8-18.7)	95% CI [0.52, 1.15], *t*(152.06) = 5.18, ***p* < .001 (a > b)**
hs CRP (mg/dl) *mean ± SD (range)*	0.27 ± 0.37 (0.01-3.91)	0.46 ± 0.71 (0.01-6.25)	95% CI [-.32, -.05], *t*(129.59) = -2.73, ***p* = .007 (a < b)**
BMI (kg/m^2) *mean ± SD (range)*	28.62 ± 5.33 (18.89-47.99)	29.29 ± 5.40 (18.31-48.51)	95% CI [-1.81, 0.47], *t*(545) = -1.15, *p* = .25
Systolic blood pressure (mmHg) *mean ± SD (range)*	144.12 ± 20.96 (92.0-249.5)	139.01 ± 21.45	95% CI [0.66, 9.57], *t*(551) = 2.26, ***p* = .024 (a > b)**
Diastolic blood pressure (mmHg) *mean ± SD (range)*	81.39 ± 11.08 (41.5-125.0)	77.23 ± 9.82	95% CI [1.86, 6.45], *t*(551) = 3.56, ***p* < .001 (a > b)**
Diabetes mellitus n (%)	95 (20.3%)	31 (27.0%)	χ^2 = 2.46, *p* = .117
Coronary heart disease n (%)	78 (16.7%)	31 (27.0%)	χ^2 = 6.32, ***p* = .01 (a < b)**
Arterial hypertension n (%)	405 (86.7%)	102 (88.7%)	χ^2 = 0.31, *p* = .58
Current medication n (%)	403 (86.3%)	105 (91.3%)	χ^2 = 4.43, ***p* = .04 (a < b)**
Dyslipidemia n (%)	201 (43.0%)	51 (44.3%)	χ^2 = 0.18, *p* = .68

Asthma bronchiale n (%)	34 (7.3%)	13 (11.3%)	χ^2 = 2.35, *p* = .13
Chronic obstructive bronchitis n (%)	31 (6.6%)	13 (11.3%)	χ^2 = 3.82, *p* = .05
Cancer n (%)	119 (25.5%)	39 (33.9%)	χ^2 = 4.95, ***p* = .03 (a < b)**
Psychological variables			
PHQ-15 Score (*mean* ± *SD*)	5.37 ± 4.19	6.78 ± 4.20	95% CI [-2.35, -0.47], *t*(511) = -2.94, ***p* = .003 (a < b)**
PHQ-9 Score (*mean* ± *SD*)	3.40 ± 3.52	4.06 ± 3.33	95% CI [-1.44, 0.11], *t*(511) = -1.68, *p* = .09
GAD7 Score (*mean* ± *SD*)	2.44 ± 2.94	2.60 ± 2.73	95% CI [-0.82, 4.87], *t*(507) = -0.502, *p* = .62
ACE Score (*mean* ± *SD*)	1.10 ± 1.53	1.07 ± 1.52	95% CI [-0.32, 0.38], *t*(490) = 0.17, *p* = .86
EQ5D Score (*mean* ± *SD*)	0.88 ± .016	0.84 ± 0.15	95% CI [0.10, 0.08], *t*(514) = 2.54, ***p* = .01 (a > b)**

Note: Sample sizes across variables may differ due to missing values. Bold types stand for significant values.

CKD, chronic kidney disease; eGFR, estimated glomerular filtration rate; hsCRP, highly sensitive C-reactive protein; BMI, Body-Mass-Index; PHQ-15, Patient-Health-Questionnaire-15; PHQ-9, Patient-Health-Questionnaire-9; GAD-7, Generalized-Anxiety-Disorder-7; ACE, Adverse Childhood Experiences; EQ5D-5L, European Quality of Life 5 Dimensions 5 Level Version; n, number; CI, confidence interval; p, p-value χ^2, chi-square coefficient; SD, standard deviation;

Table S5: Symptom amount measured with PHQ-15 – comparison of CKD stages

Characteristic	**Stage 3a (45-59)[a]**	**Stage 3b, 4 & 5 (44-<15)[b]**	**comparison**
n	469	99	
PHQ-15 variables			
Stomach Pain n (%)	57 (12.2%)	16 (13.9%)	χ^2 = .245, *p* = .62
Back Pain n (%)	247 (52.9%)	57 (49.6%)	χ^2 = .409, *p* = .52
Pain in your arms, legs, or joints (knee, hips, etc.) n (%)	286 (61.2%)	74 (64.3%)	χ^2 = .377, *p* = .54
Menstrual cramps or other problems with your periods (women only) n (%)	4 (0.9%)	0 (0%)	χ^2 = .992, *p* = .32
Pain or problems during sexual intercourse n (%)	96 (20.6%)	31 (27.0%)	χ^2 = 2.22, *p* = .14
Headaches n (%)	91 (19.5%)	27 (23.5%)	χ^2 = .910 *p* = .34
Chest pain n (%)	54 (11.6%)	13 (11.3%)	χ^2 = .006 *p* = .94
Dizziness n (%)	120 (25.7%)	35 (30.4%)	χ^2 = 1.06, *p* = .30
Fainting spells n (%)	6 (1.3%)	3 (2.6%)	χ^2 = 1.06, *p* = .30
Feeling your heart pound or race n (%)	83 (17.8%)	31 (27.0%)	χ^2 = 4.94, ***p* = .03 (a < b)**
Shortness of breath n (%)	160 (34.3%)	50 (43.5%)	χ^2 = 3.40, *p* = .07
Constipation, loose bowels, or diarrhoea n (%)	115 (24.6%)	39 (33.9%)	χ^2 = 4.09, ***p* = .04 (a < b)**
Nausea, gas, or indigestion n (%)	124 (26.6%)	34 (29.6%)	χ^2 = 0.42, *p* = .52
Feeling tired or having low energy n (%)	205 (43.9%)	53 (46.1%)	χ^2 = .18, *p* = .67
Trouble sleeping n (%)	214 (45.8%)	56 (48.7%)	χ^2 = .306, *p* = .58
Symptom amount (*mean* ± *SD*)	4.49 ± 3.05	5.59 ± 3.21	95% CI [-1.79, -.040], *t*(511) = -3.12, ***p* = .002 (a < b)**

Note: Sample sizes across variables may differ due to missing values. Bold types stand for significant values.

CKD, chronic kidney disease; PHQ-15, Patient-Health-Questionnaire-15; n, number; χ^2, chi-square coefficient; p, p-value; SD, standard deviation; CI, confidence interval;

Biopsychosocial correlates of somatic symptom burden in individuals with chronic kidney disease – results of the Hamburg City Health Study (HCHS)

STROBE Statement—checklist of items that should be included in reports of observational studies

	Item No	Recommendation	Page No
Title and abstract	1	(*a*) Indicate the study's design with a commonly used term in the title or the abstract	1-3
		(*b*) Provide in the abstract an informative and balanced summary of what was done and what was found	2-3
Introduction			
Background/rationale	2	Explain the scientific background and rationale for the investigation being reported	5-6
Objectives	3	State specific objectives, including any prespecified hypotheses	6
Methods			
Study design	4	Present key elements of study design early in the paper	6-7
Setting	5	Describe the setting, locations, and relevant dates, including periods of recruitment, exposure, follow-up, and data collection	6
Participants	6	(*a*) *Cohort study*—Give the eligibility criteria, and the sources and methods of selection of participants. Describe methods of follow-up *Case-control study*—Give the eligibility criteria, and the sources and methods of case ascertainment and control selection. Give the rationale for the choice of cases and controls *Cross-sectional study*—Give the eligibility criteria, and the sources and methods of selection of participants	6
		(*b*) *Cohort study*—For matched studies, give matching criteria and number of exposed and unexposed *Case-control study*—For matched studies, give matching criteria and the number of controls per case	6
Variables	7	Clearly define all outcomes, exposures, predictors, potential confounders, and effect modifiers. Give diagnostic criteria, if applicable	6-8
Data sources/ measurement	8*	For each variable of interest, give sources of data and details of methods of assessment (measurement). Describe comparability of assessment methods if there is more than one group	8-9
Bias	9	Describe any efforts to address potential sources of bias	8-9
Study size	10	Explain how the study size was arrived at	6
Quantitative variables	11	Explain how quantitative variables were handled in the analyses. If applicable, describe which groupings were chosen and why	8-9
Statistical methods	12	(*a*) Describe all statistical methods, including those used to control for confounding	8-9
		(*b*) Describe any methods used to examine subgroups and interactions	8-9
		(*c*) Explain how missing data were addressed	8-9

		(*d*) *Cohort study*—If applicable, explain how loss to follow-up was addressed *Case-control study*—If applicable, explain how matching of cases and controls was addressed *Cross-sectional study*—If applicable, describe analytical methods taking account of sampling strategy	6, 9
		(*e*) Describe any sensitivity analyses	n.a.

Continued on next page

Results

Participants	13*	(a) Report numbers of individuals at each stage of study—eg numbers potentially eligible, examined for eligibility, confirmed eligible, included in the study, completing follow-up, and analysed	10
		(b) Give reasons for non-participation at each stage	n.a.
		(c) Consider use of a flow diagram	n.a.
Descriptive data	14*	(a) Give characteristics of study participants (eg demographic, clinical, social) and information on exposures and potential confounders	10
		(b) Indicate number of participants with missing data for each variable of interest	10-11
		(c) *Cohort study*—Summarise follow-up time (eg, average and total amount)	n.a.
Outcome data	15*	*Cohort study*—Report numbers of outcome events or summary measures over time	10-12
		Case-control study—Report numbers in each exposure category, or summary measures of exposure	10-12
		Cross-sectional study—Report numbers of outcome events or summary measures	10-12
Main results	16	(*a*) Give unadjusted estimates and, if applicable, confounder-adjusted estimates and their precision (eg, 95% confidence interval). Make clear which confounders were adjusted for and why they were included	10-12
		(*b*) Report category boundaries when continuous variables were categorized	11
		(*c*) If relevant, consider translating estimates of relative risk into absolute risk for a meaningful time period	n.a.
Other analyses	17	Report other analyses done—eg analyses of subgroups and interactions, and sensitivity analyses	12

Discussion

Key results	18	Summarise key results with reference to study objectives	13
Limitations	19	Discuss limitations of the study, taking into account sources of potential bias or imprecision. Discuss both direction and magnitude of any potential bias	15
Interpretation	20	Give a cautious overall interpretation of results considering objectives, limitations, multiplicity of analyses, results from similar studies, and other relevant evidence	13-15
Generalisability	21	Discuss the generalisability (external validity) of the study results	13-15

Other information

Funding	22	Give the source of funding and the role of the funders for the present study and, if applicable, for the original study on which the present article is based	16

*Give information separately for cases and controls in case-control studies and, if applicable, for exposed and unexposed groups in cohort and cross-sectional studies.

Note: An Explanation and Elaboration article discusses each checklist item and gives methodological background and published examples of transparent reporting. The STROBE checklist is best used in conjunction with this article (freely available on the Web sites of PLoS Medicine at http://www.plosmedicine.org/, Annals of Internal Medicine at http://www.annals.org/, and Epidemiology at http://www.epidem.com/). Information on the STROBE Initiative is available at www.strobe-statement.org.

ICMJE DISCLOSURE FORM

Date: 9/17/2025

Your Name: Birte Jessen

Manuscript Title: Biopsychosocial correlates of somatic symptom burden in chronic kidney disease – results of the Hamburg City Health Study (HCHS)

Manuscript Number (if known): Click or tap here to enter text.

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The author's relationships/activities/interests should be defined broadly. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

In item #1 below, report all support for the work reported in this manuscript without time limit. For all other items, the time frame for disclosure is the past 36 months.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	**Specifications/Comments (e.g., if payments were made to you or to your institution)**
Time frame: Since the initial planning of the work			
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) **No time limit for this item.**	☐ **None**	
		MSH Medical School Hamburg, Hamburg, Germany	Limited contract (until 09/25), 26h weekly
		University Medical Center Hamburg-Eppendorf	Limited contract as part of the non-medical phd programs (until 01/26)
			Click the tab key to add additional rows.
Time frame: past 36 months			
2	Grants or contracts from any entity (if not indicated in item #1 above).	☐ **None**	
		Deutsche Forschungs-gemeinschaft (DFG, German Research Foundation), GER	Research funding for the SOMACROSS research unit (RU 5211), doctoral researcher. Payment to my institution (MSH). Funding period 10/2021 – 09/2025
3	Royalties or licenses	☒ **None**	

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
4	Consulting fees	☒ **None**	
5	Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events	☒ **None**	
6	Payment for expert testimony	☒ **None**	
7	Support for attending meetings and/or travel	☒ **None**	
8	Patents planned, issued or pending	☒ **None**	
9	Participation on a Data Safety Monitoring Board or Advisory Board	☒ **None**	
10	Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid	☒ **None**	

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
11	Stock or stock options	☒ **None**	
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services	☒ **None**	
13	Other financial or non-financial interests	☒ **None**	

Please place an "X" next to the following statement to indicate your agreement:

☒ I certify that I have answered every question and have not altered the wording of any of the questions on this form.

ICMJE DISCLOSURE FORM

Date: September 17th, 2025
Your Name: Bernd Löwe
Manuscript Title: Biopsychosocial correlates of somatic symptom burden in chronic kidney disease – results of the Hamburg City Health Study (HCHS)
Manuscript number (if known):

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the current manuscript only.

The author's relationships/activities/interests should be defined broadly. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

In item #1 below, report all support for the work reported in this manuscript without time limit. For all other items, the time frame for disclosure is the past 36 months.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	**Specifications/Comments (e.g., if payments were made to you or to your institution)**
Time frame: Since the initial planning of the work			
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) **No time limit for this item.**	University Medical Center Hamburg-Eppendorf, Hamburg, GER	My own position is 100% funded by the budget of the University Medical Center Hamburg-Eppendorf (permanent contract), Hamburg, Germany.
Time frame: past 36 months			
2	Grants or contracts from any entity (if not indicated in item #1 above).	Deutsche Forschungs-gemeinschaft (DFG, German Research Foundation), GER	Research funding for the SOMACROSS research unit (RU 5211), speaker, subproject leader, and co-applicant. Payment to my institution.
		Deutsche Forschungs-gemeinschaft (DFG, German Research Foundation), GER	Research funding for the DISCOVER project (GZ: LO 766/18-1), applicant. Payment to my institution.
		Deutsche Forschungs-gemeinschaft (DFG,	Research funding for the SOMA.COV project (GZ: LO 766/23-1), applicant. Payment to my institution.

		German Research Foundation), GER	
		Deutsche Forschungs-gemeinschaft (DFG, German Research Foundation), GER	Research funding for the PSY-HEART-II-RCT (GZ: RI 574/29-2, co-applicant. Payment to my institution.
		Bundesministerium für Bildung und Forschung (BMBF, Federal Ministry of Education and Research), GER	Research funding for the SUSTAIN-RCT (FKZ: 01KG2009), co-applicant. Payment to my institution.
		Bundesministerium für Bildung und Forschung (BMBF, Federal Ministry of Education and Research), GER	Research funding for the GUIDE-PSS project (FKZ: 01KG2211), co-principal investigator. Payment to my institution.
		Bundesministerium für Bildung und Forschung (BMBF, Federal Ministry of Education and Research), GER	Research funding for the PCOR-MII - Medical Informatics Use Case 'Patient-Centered Outcomes Research within the Medical Informatics Initiative' - Subproject: Hamburg (01ZZ2321D). Payment to my institution.
		Innovationsausschuss des Gemeinsamen Bundesausschusses (Innovation Committee at the Joint Federal Committee), GER.	Research funding for the GETFEEDBACK.GP-RCT (FKZ: 01VSF17033), principal investigator. Payment to my institution.
		Innovationsausschuss des Gemeinsamen Bundesausschusses (Innovation Committee at the Joint Federal Committee), GER.	Research funding for the INCREASE-study (FKZ: 01NVF19028), co-investigator. Payment to my institution.
		European Commission: Horizon 2020 Framework Programme, EU	Research funding for the Marie Sklodowska Curie Innovative Training Network ETUDE (project 956673), co-investigator. Payment to my institution.
		European Commission: Horizon 2020 Framework Programme, EU	Research funding for the ESCAPE project (project 945377), co-investigator. Payment to my institution.
		European Joint Programme for Rare Diseases (EJP) / Federal Ministry of Education and Research (BMBF), EU / GER	Research funding for the Q.RARE.LI study (EJPRD21-061), principal investigator. Payment to my institution.
		Federal Ministry of Health, Germany, GER	Research funding for the EMOPROM project on Post COVID-19 condition (2524FSB94D), co-investigator. Payment to my institution.
		Stiftung Psychosomatik der Wirbelsäulen-erkrankungen, Stuttgart, (Foundation	Research funding for the IDRIS and the BACKBEAT studies, principal investigator. Payment to my institution.

		Psychosomatics of Spinal Diseases, Stuttgart), GER	
3	Royalties or licenses	Elsevier	Scholarly book chapter, payment of remuneration of 1 € / year to me to me
		Thieme Publishing	Scholarly book chapter, payment of remuneration of 53 € / year to me
		Clett Kotta Publishing	Scholarly book chapter, payment of remuneration of <1 € / year to me
		Hogrefe Publishing	Self-report questionnaire (Fragebogen zum Körperbild, FKB-20; [Body Image Questionnaire]), payment of remuneration of approx. 110 €/year to me
4	Consulting fees	_x__None	
5	Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events	Norddeutscher Rundfunk (NDR	Remuneration for interviews in medical knowledge programmes on public television (150 €/interview, in total 3 interviews).
		Lindauer Psychotherapiewochen	Remuneration and travel reimbursement for a lecture at the Lindau Psychotherapy Weeks, April 2024
		University Hospital Zurich, Department of Consultation-Liaison Psychiatry and Psychosomatic Medicine	Remuneration and travel reimbursement for a lecture at the department, March 2025
6	Payment for expert testimony	Department of Clinical Medicine, Aarhus University	Committee member for a research assessment of a research center at the Department of Clinical Medicine, Aarhus University in Denmark, March 2023. Payment of a remuneration of 1200 € to me.
7	Support for attending meetings and/or travel	European Association of Psychosomatic Medicine (EAPM)	Travel costs (482 €) for a presentation of the EAPM academy held at the CONFERINȚA NAȚIONALĂ DE PSIHOSOMATICĂ, CLUJ-NAPOCA, Romania in Cluj, Romania, 20 Oct 2023. Travel allowance (€500) for a lecture on the occasion of the Alison Creed Award at the EAPM conference in Lausanne, 12-15 June 2024.
		Societatea de Medicina Biopsyhosociala, Romania	Accomodation and food for a presentation of the EAPM academy held at the CONFERINȚA NAȚIONALĂ DE PSIHOSOMATICĂ, CLUJ-NAPOCA, Romania in Cluj, Romania, 20 Oct 2023.
8	Patents planned, issued or pending	_x__None	
9	Participation on a Data Safety Monitoring Board or Advisory Board	EIFFEL Study Oversight Committee	Member of EIFFEL Study Oversight Committee, unpaid

10	Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid	German College of Psychosomatic Medicine (DKPM)	President, unpaid
		European Association of Psychosomatic Medicine (EAPM)	Past Board member, unpaid
11	Stock or stock options	_x__None	
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services	_x__None	
13	Other financial or non-financial interests	_x__None	

Please place an "X" next to the following statement to indicate your agreement:

X I certify that I have answered every question and have not altered the wording of any of the questions on this form.

ICMJE DISCLOSURE FORM

Date: 9/17/2025

Your Name: Raphael Twerenbold

Manuscript Title: Biopsychosocial correlates of somatic symptom burden in chronic kidney disease – results of the Hamburg City Health Study (HCHS)

Manuscript Number (if known): Click or tap here to enter text.

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The author's relationships/activities/interests should be defined broadly. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

In item #1 below, report all support for the work reported in this manuscript without time limit. For all other items, the time frame for disclosure is the past 36 months.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	**Specifications/Comments (e.g., if payments were made to you or to your institution)**
Time frame: Since the initial planning of the work			
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) **No time limit for this item.**	☒ None	
			Click the tab key to add additional rows.
Time frame: past 36 months			
2	Grants or contracts from any entity (if not indicated in item #1 above).	☐ **None**	
		Grants from the German Center for Cardiovascular Research (DZHK), the Kühne Foundation, the Joachim Herz Foundation, the Swiss National Science Foundation (Grant No P300PB_167803) and the Swiss Heart Foundation	To the institution

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
3	Royalties or licenses	☒ **None**	
4	Consulting fees	☐ **None**	
		Consulting honoraria from Abbott, Amgen, Astra Zeneca, Psyros, and Roche.	Personal
5	Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events	☐ **None**	
		Speaker honoraria from Abbott, Amgen, Astra Zeneca, Roche and Siemens.	Personal
6	Payment for expert testimony	☒ **None**	
7	Support for attending meetings and/or travel	☒ **None**	
8	Patents planned, issued or pending	☐ **None**	
		Co-inventor of an international patent on a computing device for estimating the probability of myocardial infarction (International Publication Numbers WO2022043229A1, TW202219980A)	Personal, Co-inventor and Co-owner
9	Participation on a Data Safety Monitoring Board or Advisory Board	☒ **None**	

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
10	Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid	☒ **None**	
11	Stock or stock options	☒ **None**	
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services	☒ **None**	
13	Other financial or non-financial interests	☐ **None**	
		Dr. Twerenbold is co-founder and shareholder of the ART-EMIS Hamburg GmbH, which holds an international patent application on a computing device for estimating the probability of myocardial infarction (see patents under 8)	Personal

Please place an "X" next to the following statement to indicate your agreement:

☒ I certify that I have answered every question and have not altered the wording of any of the questions on this form.

ICMJE DISCLOSURE FORM

Date: 9/17/2025

Your Name: Martin Härter

Manuscript Title: Biopsychosocial correlates of somatic symptom burden in chronic kidney disease – results of the Hamburg City Health Study (HCHS)

Manuscript Number (if known): Click or tap here to enter text.

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The author's relationships/activities/interests should be defined broadly. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

In item #1 below, report all support for the work reported in this manuscript without time limit. For all other items, the time frame for disclosure is the past 36 months.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	**Specifications/Comments (e.g., if payments were made to you or to your institution)**
Time frame: Since the initial planning of the work			
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) **No time limit for this item.**	☒ None	
			Click the tab key to add additional rows.
Time frame: past 36 months			
2	Grants or contracts from any entity (if not indicated in item #1 above).	☒ **None**	
		Public grants from different public institutions, but not related to the current manuscript	Only institutional funding
3	Royalties or licenses	☐ **None**	
		Elsevier, Springer and Hogrefe for books and book chapters (not related to the content of this paper)	Book royalties

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
4	Consulting fees	☐ **None**	
		Scientific advisor for Deloitte (for a research proposal in 2024), not related to the manuscript	Personal fee
5	Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events	☒ **None**	
6	Payment for expert testimony	☒ **None**	
7	Support for attending meetings and/or travel	☒ **None**	
8	Patents planned, issued or pending	☒ **None**	
9	Participation on a Data Safety Monitoring Board or Advisory Board	☐ **None**	
		Spokesperson of the advisory board, Agency for Quality in Medicine (Berlin) (2016-2024), not related to the manuscript	Personal fee
10	Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid	☐ **None**	
		Executive officer of the German Network of Health Services Research	No fees

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
11	Stock or stock options	☒ **None**	
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services	☒ **None**	
13	Other financial or non-financial interests	☒ **None**	

Please place an "X" next to the following statement to indicate your agreement:

☒ I certify that I have answered every question and have not altered the wording of any of the questions on this form.

ICMJE DISCLOSURE FORM

Date: 9/17/2025

Your Name: Volker Harth

Manuscript Title: Biopsychosocial correlates of somatic symptom burden in chronic kidney disease – results of the Hamburg City Health Study (HCHS)

Manuscript Number (if known): Click or tap here to enter text.

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The author's relationships/activities/interests should be defined broadly. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

In item #1 below, report all support for the work reported in this manuscript without time limit. For all other items, the time frame for disclosure is the past 36 months.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	**Specifications/Comments (e.g., if payments were made to you or to your institution)**
Time frame: Since the initial planning of the work			
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) **No time limit for this item.**	☒ None	
			Click the tab key to add additional rows.
Time frame: past 36 months			
2	Grants or contracts from any entity (if not indicated in item #1 above).	☒ **None**	
3	Royalties or licenses	☒ **None**	

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
4	Consulting fees	☒ **None**	
5	Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events	☒ **None**	
6	Payment for expert testimony	☒ **None**	
7	Support for attending meetings and/or travel	☒ **None**	
8	Patents planned, issued or pending	☒ **None**	
9	Participation on a Data Safety Monitoring Board or Advisory Board	☒ **None**	
10	Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid	☒ **None**	

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
11	Stock or stock options	☒ **None**	
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services	☒ **None**	
13	Other financial or non-financial interests	☒ **None**	

Please place an "X" next to the following statement to indicate your agreement:

☒ I certify that I have answered every question and have not altered the wording of any of the questions on this form.

ICMJE DISCLOSURE FORM

Date: 9/17/2025

Your Name: Hanno Hoven

Manuscript Title: Biopsychosocial correlates of somatic symptom burden in chronic kidney disease – results of the Hamburg City Health Study (HCHS))

Manuscript Number (if known): Click or tap here to enter text.

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The author's relationships/activities/interests should be defined broadly. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

In item #1 below, report all support for the work reported in this manuscript without time limit. For all other items, the time frame for disclosure is the past 36 months.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	**Specifications/Comments (e.g., if payments were made to you or to your institution)**
Time frame: Since the initial planning of the work			
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) **No time limit for this item.**	☒ None	
			Click the tab key to add additional rows.
Time frame: past 36 months			
2	Grants or contracts from any entity (if not indicated in item #1 above).	☒ **None**	
3	Royalties or licenses	☒ **None**	

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
4	Consulting fees	☒ **None**	
5	Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events	☒ **None**	
6	Payment for expert testimony	☒ **None**	
7	Support for attending meetings and/or travel	☒ **None**	
8	Patents planned, issued or pending	☒ **None**	
9	Participation on a Data Safety Monitoring Board or Advisory Board	☒ **None**	
10	Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid	☒ **None**	

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
11	Stock or stock options	☒ **None**	
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services	☒ **None**	
13	Other financial or non-financial interests	☒ **None**	

Please place an "X" next to the following statement to indicate your agreement:

☒ I certify that I have answered every question and have not altered the wording of any of the questions on this form.

ICMJE DISCLOSURE FORM

Date: 9/17/2025

Your Name: Christian Schmidt-Lauber

Manuscript Title: Biopsychosocial correlates of somatic symptom burden in chronic kidney disease – results of the Hamburg City Health Study (HCHS)

Manuscript Number (if known): Click or tap here to enter text.

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The author's relationships/activities/interests should be defined broadly. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

In item #1 below, report all support for the work reported in this manuscript without time limit. For all other items, the time frame for disclosure is the past 36 months.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	**Specifications/Comments (e.g., if payments were made to you or to your institution)**
Time frame: Since the initial planning of the work			
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) **No time limit for this item.**	☐ None	
		Federal Ministry of Education and Research	
			Click the tab key to add additional rows.
Time frame: past 36 months			
2	Grants or contracts from any entity (if not indicated in item #1 above).	☐ **None**	
		Dr. Werner Jackstädt Foundation	
		City of Hamburg	
		Else Kröner-Forschungskolleg „Research Center on Rare Kidney Diseases (RECORD)"	
3	Royalties or licenses	☒ **None**	

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
4	Consulting fees	☒ **None**	
5	Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events	☐ **None**	
		BionTech	Honorary for lecture
6	Payment for expert testimony	☒ **None**	
7	Support for attending meetings and/or travel	☒ **None**	
8	Patents planned, issued or pending	☒ **None**	
9	Participation on a Data Safety Monitoring Board or Advisory Board	☒ **None**	
10	Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid	☒ **None**	

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
11	Stock or stock options	☒ **None**	
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services	☒ **None**	
13	Other financial or non-financial interests	☒ **None**	

Please place an "X" next to the following statement to indicate your agreement:

☒ I certify that I have answered every question and have not altered the wording of any of the questions on this form.

ICMJE DISCLOSURE FORM

Date: 9/17/2025

Your Name: Tobias B. Huber

Manuscript Title: Biopsychosocial correlates of somatic symptom burden in chronic kidney disease – results of the Hamburg City Health Study (HCHS)

Manuscript Number (if known): Click or tap here to enter text.

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The author's relationships/activities/interests should be defined broadly. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

In item #1 below, report all support for the work reported in this manuscript without time limit. For all other items, the time frame for disclosure is the past 36 months.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	**Specifications/Comments (e.g., if payments were made to you or to your institution)**
Time frame: Since the initial planning of the work			
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) **No time limit for this item.**	☐ None	
			Tobias B. Huber was supported by the DFG (*Deutsch Forschungsgemeinschaft*, German Research Foundation; CRC1192, HU 1016/8-2, HU 1016/11-1, HU 1016/ 12-1), and by the BMBF (*Bundesministerium für Bildung und Forschung,* Federal Ministry of Education and Research; STOP-FSGS-01GM2202A, NephrESA-031L0191E and UPTAKE-01EK2105D).
			Click the tab key to add additional rows.
Time frame: past 36 months			
2	Grants or contracts from any entity (if not indicated in item #1 above).	☐ **None**	
		Amicus Therapeutics	
		Genzyme/Sanofi	
		Unicyte/Fresenius Medical Care	
3	Royalties or licenses	☒ **None**	

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
4	Consulting fees	☐ **None**	
		Alexion Pharma Germany	
		AstraZeneca	
		Bayer	
		Beren Therapeutics	
		Boehringer Ingelheim Pharma	
		DaVita	
		Euroimmun	
		NIPOKA	
		Novartis Pharma	
		Pfizer Pharma	
		RenoVate Therapeutics	
		Retrophin-Travere	
		Sanofi	
		Unicyte/Fresenius Medical Care	
		Vifor Pharma	
5	Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events	☐ **None**	
		Alexion Pharma Germany	
		AstraZeneca	
		Bayer	
		Boehringer Ingelheim Pharma	
		Beren Therapeutics	
		DaVita	
		Euroimmun	
		NIPOKA	
		Novartis Pharma	
		Pfizer Pharma	
		RenoVate Therapeutics	
		Retrophin-Travere	
		Sanofi	
		Unicyte/ Fresenius Medical Care	
		Vifor Pharma	
6	Payment for expert testimony	☐ **None**	
		Alexion Pharma Germany	
		Bayer AstraZeneca	
		Beren Therapeutics	
		Boehringer Ingelheim Pharma	
		DaVita	
		Euroimmun	
		NIPOKA	
		Novartis Pharma	
		Pfizer Pharma	
		RenoVate Therapeutics	
		Retrophin-Travere	
		Sanofi	

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
7	Support for attending meetings and/or travel	☐ **None**	
		Alexion Pharma Germany	
		AstraZeneca	
		Bayer	
		Beren Therapeutics	
		Boehringer Ingelheim Pharma	
		DaVita	
		Euroimmun	
		NIPOKA	
		Novartis Pharma	
		Pfizer Pharma	
		RenoVate Therapeutics	
		Retrophin-Travere	
		Sanofi	
		Unicyte/Fresenius Medical Care	
		Vifor Pharma	
8	Patents planned, issued or pending	☐ **None**	
			European patent application EP23154267.1 “AN AAV2-VECTOR VARIANT FOR TARGETED TRANSFER OF GENES” Filing date: 31.01.2023; International subsequent PCT-application planned; Patent applications will be regularly published by the Patent Office starting July 31st, 2024, so the application is not yet in the patent databases
			European patent application EP23154266.3 “AN AAV9 CAPSID VARIANT FOR TARGETED GENE TRANSFER” Filing date: 31.01.2023; International subsequent PCT-application planned; Patent applications will be regularly published by the Patent Office starting July 31st, 2024, so the application is not yet in the patent databases
			European patent application EP23195461.1 “Organ Perfusion Solution” Filing date: 05.09.2023
9	Participation on a Data Safety Monitoring Board or Advisory Board	☒ **None**	
10	Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid	☐ **None**	
			President of the International Society of Glomerular Disease
			Editorial Board of Kidney International
			Advisory Board of Nature Reviews Nephrology

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
11	Stock or stock options	☒ **None**	
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services	☒ **None**	
13	Other financial or non-financial interests	☒ **None**	

Please place an "X" next to the following statement to indicate your agreement:

☒ I certify that I have answered every question and have not altered the wording of any of the questions on this form.

ICMJE DISCLOSURE FORM

Date: 9/17/2025

Your Name: Meike Shedden-Mora

Manuscript Title: Biopsychosocial correlates of somatic symptom burden in chronic kidney disease – results of the Hamburg City Health Study (HCHS)

Manuscript Number (if known): Click or tap here to enter text.

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The author's relationships/activities/interests should be defined broadly. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

In item #1 below, report all support for the work reported in this manuscript without time limit. For all other items, the time frame for disclosure is the past 36 months.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	**Specifications/Comments (e.g., if payments were made to you or to your institution)**
Time frame: Since the initial planning of the work			
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) **No time limit for this item.**	☐ None	
		MSH Medical School Hamburg, Hamburg, Germany	Permanent contract (full time)
		University Medical Center Hamburg-Eppendorf, Hamburg, Germany	Limited contract (until 09/25), 1,5 hours weekly
Time frame: past 36 months			
2	Grants or contracts from any entity (if not indicated in item #1 above).	☐ **None**	
		Deutsche Forschungs-gemeinschaft (DFG, German Research Foundation), GER	Research funding for the SOMACROSS research unit (RU 5211), subproject leader. Payment to my institution (MSH). Funding period 10/2021 – 09/2025
		Deutscher Akademischer Austauschdienst (DAAD, German Academic Research Service	Funding for research exchange programme to UNSW Sydney, Australia. Payment to my institution (MSH). Funding period 01/2024 – 12/2025
		Deutsche Forschungs-gemeinschaft (DFG, German Research Foundation), GER	Research funding for the Transregional Research Unit Treatment Expectation (TRR 289), subproject leader. Payment to my institution (MSH). Funding period 07/2024 – 08/2028

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
3	Royalties or licenses	☐ **None**	
		University of Toledo, USA	Honoraria for review of grant proposal (350$), paid to me (2023)
4	Consulting fees	☐ **None**	
		Norddeutscher Rundfunk (NDR), Hamburg, Germany	Remuneration for interviews in medical knowledge programmes on public television (150 - 200 €/interview, in total 7 interviews).
		Hafencity-Institut für Psychotherapieausbildung (HIP), Hamburg, Germany	Honoraria for post graduate training for psychotherapy (1600 €, in total 5 trainings), paid to me
		Institut für Psychotherapieausbildung (IfP), Hamburg, Germany	Honoraria for post graduate training for psychotherapy (1400 €, in total 4 trainings), paid to me
		Institut für Psychotherapieausbildung Marburg (IPAM), Marburg, Germany	Honoraria for post graduate training for psychotherapy (1000 €, in total 3 trainings), paid to me
5	Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events	☒ **None**	
6	Payment for expert testimony	☒ **None**	
7	Support for attending meetings and/or travel	☒ **None**	
8	Patents planned, issued or pending	☒ **None**	

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
9	Participation on a Data Safety Monitoring Board or Advisory Board	☐ **None**	
		PKD Cure e.V.	Member of the Scientific Advisory Board, unpaid
10	Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid	☐ **None**	
		European Association of Psychosomatic Medicine (EAPM)	Executive Board Member, Vice-Treasurer, unpaid
11	Stock or stock options	☒ **None**	
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services	☒ **None**	
13	Other financial or non-financial interests	☒ **None**	

Please place an "X" next to the following statement to indicate your agreement:

☒ I certify that I have answered every question and have not altered the wording of any of the questions on this form.

March, 31st 2025